MCID: NSP012
MIFTS: 66

Nasopharyngeal Carcinoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Respiratory diseases, Gastrointestinal diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

Aliases & Descriptions for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 54 12 50 56 52 14 69
Malignant Neoplasm of Nasopharynx 12 69
Nasopharyngeal Neoplasms 42 69
Nasopharynx Carcinoma 12 14
Nasopharyngeal Cancer 50 29
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx Nos 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Malignant Neoplasm of Nasopharyngeal Wall Nos 12
Malignant Neoplasm of Nasopharynx [ambiguous] 12
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Cancer of Nasopharynx 69
Nasopharynx Cancer 12

Characteristics:

Orphanet epidemiological data:

56
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

32
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 56  
Rare respiratory diseases


External Ids:

OMIM 54 607107
Disease Ontology 12 DOID:9261
MeSH 42 D009303
NCIt 47 C9321
Orphanet 56 ORPHA150
MESH via Orphanet 43 C538339
UMLS via Orphanet 70 C2931822
ICD10 via Orphanet 34 C11.0 C11.1 C11.2 more

Summaries for Nasopharyngeal Carcinoma

OMIM : 54 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental... (607107) more...

MalaCards based summary : Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to nasopharyngeal carcinoma, 3 and nasopharyngeal carcinoma 2, and has symptoms including neoplasia of the nasopharynx, headache and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and MicroRNAs in cancer. The drugs Cisplatin and Erythromycin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and endothelial, and related phenotypes are liver/biliary system and neoplasm

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 71 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma, 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
id Related Disease Score Top Affiliating Genes
1 nasopharyngeal carcinoma, 3 12.2
2 nasopharyngeal carcinoma 2 12.1
3 nasopharyngeal cancer, childhood 11.9
4 lymphoepithelioma-like carcinoma 11.3
5 nasopharyngitis 11.1
6 linitis plastica 10.4 CDH1 TP53
7 clear cell adenofibroma 10.4 CDKN2A TP53
8 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
9 wolffian adnexal neoplasm 10.4 EGFR TP53
10 endometrial squamous cell carcinoma 10.3 CDKN2A RASSF1 TP53
11 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
12 thymus squamous cell carcinoma 10.3 CDKN2A EGFR TP53
13 secondary hyperparathyroidism of renal origin 10.3 CDKN2A EGFR TP53
14 myxedema 10.3 CDKN2A EGFR TP53
15 nodular cutaneous amyloidosis 10.3 CDH1 CDKN2A TP53
16 allergic contact dermatitis 10.3 CDKN2A EGFR TP53
17 advanced sleep phase syndrome 10.3 CDH1 CDKN2A TP53
18 pityriasis rosea 10.3 CDKN2A EGFR TP53
19 fallopian tube leiomyosarcoma 10.3 CDH1 CDKN2A TP53
20 interstitial lung disease 10.3 CDKN2A EGFR TP53
21 ossifying fibromyxoid tumor 10.3 CDKN2A CYP2E1 TP53
22 sengers syndrome 10.3 CDH1 CDKN2A EGFR
23 maxillary sinus cholesteatoma 10.3 CDH1 CDKN2A TP53
24 pericardium leiomyoma 10.3 CDKN2A TP53
25 chondrodysplasia punctata, rhizomelic, type 3 10.3 CASP3 TP53
26 estrogen-receptor positive breast cancer 10.3 CDH1 CDKN2A EGFR TP53
27 pyomyositis 10.3 CDH1 CDKN2A EGFR TP53
28 cleft palate cardiac defect ectrodactyly 10.3 EGFR RASSF1 TP53
29 anaerobic meningitis 10.3 EGFR HLA-A NME1
30 paroxysmal nocturnal hemoglobinuria 10.3 CDH1 CDKN2A EGFR TP53
31 progesterone-receptor positive breast cancer 10.3 CDH1 CDKN2A EGFR TP53
32 pancreatic cancer 10.3 CDH1 TP53 ZMYND10
33 pearson syndrome 10.3 CDH1 CDKN2A EGFR TP53
34 prostatic adenoma 10.3 CDKN2A EGFR TP53
35 dental caries 10.3 CDH1 EGFR NME1 TP53
36 nasal cavity disease 10.3 CDH1 EGFR NME1 TP53
37 marginal zone b-cell lymphoma 10.3 CDKN2A EGFR TP53
38 papillary transitional carcinoma 10.3 CASP3 CDH1 TP53
39 traumatic brain injury 10.3 CASP3 CDH1 CDKN2A TP53
40 breast malignant phyllodes tumor 10.3 CDH1 EGFR NME1 TP53
41 hepatic flexure cancer 10.3 CDKN2A EGFR NME1 TP53
42 oral squamous cell carcinoma 10.3 CDH1 EGFR TP53
43 fallopian tube adenocarcinoma 10.3 CASP3 CDKN2A RASSF1 TP53
44 adult medulloblastoma 10.3 CASP3 CDH1 EGFR TP53
45 hypogonadotropic hypogonadism 20 with or without anosmia 10.3 CDH1 CDKN2A EGFR TP53
46 bronchitis 10.3 CDH1 TP53
47 lattice corneal dystrophy 10.2 CASP3 CDKN2A NME1 TP53
48 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 CDH1 CDKN2A EGFR RASSF1 TP53
49 ocular melanoma 10.2 CDH1 CDKN2A EGFR TP53
50 occlusion precerebral artery 10.2 CDKN2A EGFR TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Clinical features from OMIM:

607107

Human phenotypes related to Nasopharyngeal Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 32 HP:0100630

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, rhinorrhea

MGI Mouse Phenotypes related to Nasopharyngeal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.5 EGFR MST1R NME1 RASSF1 TP53 CDKN2A
2 neoplasm MP:0002006 9.23 CDH1 CDKN2A CYP2E1 EGFR NME1 PSMB9

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
3
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124 9877265
6 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
7 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
10 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
11 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Erythromycin Estolate Phase 4
14 Erythromycin Ethylsuccinate Phase 4
15 Erythromycin stearate Phase 4
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
18 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
20 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2
24 Cholinergic Agents Phase 4,Phase 3,Phase 2
25 Nicotinic Agonists Phase 4
26 Central Nervous System Stimulants Phase 4,Phase 3
27
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
28
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
29
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
30
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
31
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
32
Sulindac Approved Phase 3,Phase 2 38194-50-2 5352 1548887
33
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
34
Budesonide Approved Phase 3 51333-22-3 63006 5281004
35
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
36
Nedaplatin Approved Phase 3,Phase 1,Phase 2 95734-82-0
37 Tegafur Approved Phase 3,Phase 2 17902-23-7
38
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
39
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
40
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
41
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
42
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
43
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
44
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
45
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
46
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
47
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
48
Bleomycin Approved Phase 3 11056-06-7 5360373
49
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
50
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 594)
id Name Status NCT ID Phase
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
2 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
4 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Recruiting NCT02293356 Phase 4
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
6 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Recruiting NCT03069820 Phase 4
7 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
8 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Not yet recruiting NCT02354560 Phase 4
9 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) Terminated NCT00140894 Phase 4
10 Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients Terminated NCT00151476 Phase 4
11 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3
12 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3
13 Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma Unknown status NCT02089204 Phase 2, Phase 3
14 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3
15 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3
16 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3
17 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3
18 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3
19 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3
20 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3
21 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3
22 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3
23 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
24 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Unknown status NCT01197612 Phase 3
25 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3
26 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Unknown status NCT00117572 Phase 3
27 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3
28 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3
29 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3
30 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3
31 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
32 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
33 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
34 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3
35 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
36 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
37 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
38 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
39 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
40 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
41 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3
42 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
43 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3
44 Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor Completed NCT00047125 Phase 3
45 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3
46 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed NCT00101582 Phase 3
47 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3
48 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Exten Completed NCT01622569 Phase 3
49 Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections Completed NCT01613365 Phase 3
50 Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx Completed NCT00051441 Phase 3

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

id Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

39
Skin, Lymph Node, Endothelial, T Cells, Lung, Thyroid, Tongue

The Foundational Model of Anatomy Ontology organs/tissues related to Nasopharyngeal Carcinoma:

18
The Nasopharynx

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 1525)
id Title Authors Year
1
Long non-coding RNA LOC100129148 functions as an oncogene in human nasopharyngeal carcinoma by targeting miR-539-5p. ( 28328537 )
2017
2
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. ( 27923823 )
2017
3
MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1. ( 28075468 )
2017
4
miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. ( 28315691 )
2017
5
Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area. ( 28493307 )
2017
6
A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population. ( 28498819 )
2017
7
Depletion of NFBD1/MDC1 Induces Apoptosis in Nasopharyngeal Carcinoma Cells Through the p53-ROS-Mitochondrial Pathway. ( 28081741 )
2017
8
(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results. ( 28091565 )
2017
9
CYP2E1 polymorphisms and nasopharyngeal carcinoma risk: a meta-analysis. ( 27491320 )
2017
10
Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma. ( 28061788 )
2017
11
Three-Phase Adaptive Radiation Therapy for Patients With Nasopharyngeal Carcinoma Undergoing Intensity-Modulated Radiation Therapy: Dosimetric Analysis. ( 28511585 )
2017
12
Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells. ( 28496336 )
2017
13
2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-I_B/HIF-1 signaling pathway inactivation and EMT reversal. ( 28000883 )
2017
14
Epigallocatechin-3-gallate Modulates MicroRNA Expression Profiles in Human Nasopharyngeal Carcinoma CNE2 Cells. ( 28051030 )
2017
15
Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study. ( 28532605 )
2017
16
Prognostic value of cervical nodal tumor volume in nasopharyngeal carcinoma: Analysis of 1230 patients with positive cervical nodal metastasis. ( 28489930 )
2017
17
Comparison of the efficacy between intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in stage II nasopharyngeal carcinoma. ( 28498818 )
2017
18
Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review. ( 28053541 )
2017
19
Downregulated ECRG4 is correlated with lymph node metastasis and predicts poor outcome for nasopharyngeal carcinoma patients. ( 27119734 )
2017
20
PKCI+ promotes local advancement via its dual roles in nasopharyngeal carcinoma. ( 28084179 )
2017
21
Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( 28493838 )
2017
22
miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma. ( 28053597 )
2017
23
Interaction between miR-572 and PPP2R2C and their effects on proliferation, migration and invasion of nasopharyngeal carcinoma (NPC) cells. ( 28525724 )
2017
24
Associations of lifestyle and diet with the risk of nasopharyngeal carcinoma in Singapore: a case-control study. ( 28063457 )
2017
25
Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? ( 28529609 )
2017
26
Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via EGFR/Ca(2+)/calpain/ITGI^4 axis. ( 28512118 )
2017
27
Histogram analysis of diffusion kurtosis imaging of nasopharyngeal carcinoma: Correlation between quantitative parameters and clinical stage. ( 28525383 )
2017
28
Inhibition of N-acetylglucosaminyltransferase V enhances the cetuximab-induced radiosensitivity of nasopharyngeal carcinoma cells likely through EGFR N-glycan alterations. ( 28535302 )
2017
29
Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. ( 27916418 )
2017
30
Oleuropein enhances radiation sensitivity of nasopharyngeal carcinoma by downregulating PDRG1 through HIF1I+-repressed microRNA-519d. ( 28057028 )
2017
31
MiR-130a-3p inhibits the viability, proliferation, invasion, and cell cycle and promotes apoptosis of nasopharyngeal carcinoma cells by suppressing BACH2 expression. ( 28487475 )
2017
32
Laminaria Japonica Polysaccharides effectively inhibited the growth of nasopharyngeal carcinoma cells in vivo and in vitro study. ( 28501488 )
2017
33
EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma. ( 28347228 )
2017
34
HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis. ( 27535842 )
2017
35
BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma. ( 28083995 )
2017
36
Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma. ( 28515352 )
2017
37
Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3. ( 28240350 )
2017
38
Higher N stage and serum ferritin, but lower serum albumin levels are associated with distant metastasis and poor survival in patients with nasopharyngeal carcinoma following intensity-modulated radiotherapy. ( 28500850 )
2017
39
Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. ( 28078787 )
2017
40
Long-term Patterns of Regional Failure for Nasopharyngeal Carcinoma following Intensity-Modulated Radiation Therapy. ( 28529611 )
2017
41
Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma. ( 28070838 )
2017
42
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma. ( 28351314 )
2017
43
MicroRNA-212 inhibits the metastasis of nasopharyngeal carcinoma by targeting SOX4. ( 28504814 )
2017
44
Minicircle-oriP-miR-31 as a Novel EBNA1-specific miRNA Therapy Approach for Nasopharyngeal Carcinoma. ( 28042945 )
2017
45
Influence of Cervical Node Necrosis of Different Grades on the Prognosis of Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy. ( 28529607 )
2017
46
Oncogenic role of the TP53-induced glycolysis and apoptosis regulator in nasopharyngeal carcinoma through NF-I_B pathway modulation. ( 26691054 )
2016
47
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials. ( 27640138 )
2016
48
MicroRNA-124-3p inhibits the growth and metastasis of nasopharyngeal carcinoma cells by targeting STAT3. ( 26707908 )
2016
49
I^-Catenin is important for cancer stem cell generation and tumorigenic activity in nasopharyngeal carcinoma. ( 27177749 )
2016
50
Overexpression of JAK2: a predictor of unfavorable prognosis for nasopharyngeal carcinoma. ( 27086650 )
2016

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show all 15)
id Gene Variation Type Significance SNP ID Assembly Location
1 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
2 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
3 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
5 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
8 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
9 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
10 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
11 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
12 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
13 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
14 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
15 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 551)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 13
2 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 13
3 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 13
4 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 13
5 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 13
6 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 13
7 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 13
8 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 13
9 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 13
10 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 13
11 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 13
12 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 13
13 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 13
14 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 13
15 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 13
16 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 13
17 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 13
18 COSM1739496 TNKS upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.583G>A p.V195M 13
19 COSM4996454 TMPRSS11E upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.268G>T p.A90S 13
20 COSM4996730 TFAP2D upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.767C>A p.A256E 13
21 COSM4996391 TET2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4250T>G p.V1417G 13
22 COSM4996618 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.21845G>C p.W7282S 13
23 COSM4996643 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.7996C>A p.Q2666K 13
24 COSM4996628 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.14707G>T p.V4903L 13
25 COSM4996653 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5827G>A p.E1943K 13
26 COSM4996638 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8339T>C p.L2780P 13
27 COSM4996648 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6506C>T p.T2169I 13
28 COSM4995726 SPACA3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.376A>G p.N126D 13
29 COSM4994835 SORCS3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3082G>A p.V1028I 13
30 COSM4995636 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1682A>G p.Y561C 13
31 COSM2128623 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2699A>G p.N900S 13
32 COSM4996349 SMARCC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2927G>C p.G976A 13
33 COSM4997191 SLITRK3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.796C>T p.H266Y 13
34 COSM4996929 SLC7A2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.296C>A p.A99E 13
35 COSM4997189 SLC19A1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.758G>T p.R253L 13
36 COSM4995400 SIPA1L2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2574C>A p.H858Q 13
37 COSM2167722 SF3A3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1081G>A p.E361K 13
38 COSM4996346 SETD2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3808C>T p.R1270C 13
39 COSM4996834 SDK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6347T>G p.L2116R 13
40 COSM971349 SALL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2582C>T p.S861L 13
41 COSM1332064 S1PR1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.424C>T p.R142C 13
42 COSM4996889 RSPO2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.508G>T p.E170* 13
43 COSM4994974 RRM1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2377T>C p.*793R 13
44 COSM4996749 RIMS1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4475G>A p.G1492D 13
45 COSM4995079 RFX4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.716T>A p.M239K 13
46 COSM4996611 REPS1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1696C>T p.Q566* 13
47 COSM577363 PTPRT upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4036C>T p.R1346W 13
48 COSM4995349 PTPRC upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3139A>G p.M1047V 13
49 COSM4997091 PTCH1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3536G>A p.G1179E 13
50 COSM4995197 PSPC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1098C>A p.H366Q 13

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

GO Terms for Nasopharyngeal Carcinoma

Cellular components related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 EGFR HLA-A MST1R THY1 TMEM8B

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of B cell proliferation GO:0030889 9.26 CASP3 CDKN2A
2 replicative senescence GO:0090399 9.16 CDKN2A TP53
3 Ras protein signal transduction GO:0007265 9.13 CDKN2A RASSF1 TP53
4 cellular response to drug GO:0035690 8.8 EGFR NME1 TP53

Molecular functions related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.35 CDKN2A EGFR NME1 THY1 TP53
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CASP3 CDKN2A
3 enzyme binding GO:0019899 9.02 CYP2E1 EGFR MST1R THY1 TP53

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....